Nanotechnology-Based Vaccines
Abstract
Keywords
Full Text:
PDFReferences
Doria-Rose, N., Suthar, M. S., Makowski, M., OConnell, S., McDermott, A. B., Flach, B., mRNA-1273 Study Group. (2021). Antibody persistence through 6 months after the second dose of mRNA-1273 vaccine for covid-19. The New England Journal of Medicine, 384(23), 22592261. doi:10.1056/NEJMc2103916.
Braz Gomes, K., DSa, S., Allotey-Babington, G. L., Kang, S.-M., & DSouza, M. J. (2021). Transdermal vaccination with the matrix-2 protein virus-like particle (M2e VLP) induces immunity in mice against influenza A virus. Vaccines, 9(11), 1324. doi:10.3390/vaccines9111324
Bachmann, M. F., & Jennings, G. T. (2010). Vaccine delivery: a matter of size, geometry, kinetics, and molecular patterns. Nature Reviews. Immunology, 10(11), 787796. doi:10.1038/nri2868
Bachmann, M. F., Rohrer, U. H., Kndig, T. M., Brki, K., Hengartner, H., & Zinkernagel, R. M. (1993). The influence of antigen organization on B cell responsiveness. Science (New York, N.Y.), 262(5138), 14481451. doi:10.1126/science.8248784
Baranov, M. V., Kumar, M., Sacanna, S., Thutupalli, S., & van den Bogaart, G. (2020). Modulation of immune responses by particle size and shape. Frontiers in Immunology, 11, 607945. doi:10.3389/fimmu.2020.607945
de Souza, G. A. P., Rocha, R. P., Gonalves, R. L., Ferreira, C. S., de Mello Silva, B., de Castro, R. F. G., Coelho, L. F. L. (2021). Nanoparticles as vaccines to prevent arbovirus infection: A long road ahead. Pathogens, 10(1), 36. doi:10.3390/pathogens10010036
Abo-zeid, Y., & Garnett, M. C. (2020). Polymer nanoparticle as a delivery system for ribavirin: Do nanoparticle avoid uptake by Red Blood Cells? Journal of Drug Delivery Science and Technology, 56(101552), 101552. doi:10.1016/j.jddst.2020.101552
Chen, L., & Liang, J. (2020). An overview of functional nanoparticles as novel emerging antiviral therapeutic agents. Materials Science & Engineering. C, Materials for Biological Applications, 112(110924), 110924. doi:10.1016/j.msec.2020.110924
Chen, N., Zheng, Y., Yin, J., Li, X., & Zheng, C. (2013). Inhibitory effects of silver nanoparticles against adenovirus type 3 in vitro. Journal of Virological Methods, 193(2), 470477. doi:10.1016/j.jviromet.2013.07.020
Choi, A., Koch, M., Wu, K., Chu, L., Ma, L., Hill, A., Edwards, D. K. (2021). Safety and immunogenicity of SARS-CoV-2 variant mRNA vaccine boosters in healthy adults: an interim analysis. Nature Medicine, 27(11), 20252031. doi:10.1038/s41591-021-01527-y
Chen, L., Valentine, J. L., Huang, C.-J., Endicott, C. E., Moeller, T. D., Rasmussen, J. A., DeLisa, M. P. (2016). Outer membrane vesicles displaying engineered glycotopes elicit protective antibodies. Proceedings of the National Academy of Sciences of the United States of America, 113(26), E3609-18. doi:10.1073/pnas.1518311113
Heinz, H., Pramanik, C., Heinz, O., Ding, Y., Mishra, R. K., Marchon, D., Ziolo, R. F. (2017). Nanoparticle decoration with surfactants: Molecular interactions, assembly, and applications. Surface Science Reports, 72(1), 158. doi:10.1016/j.surfrep.2017.02.001
Alimehmeti, I. (2021). Efficacy and Safety of AZD1222, BNT162b2 and mRNA-1273 vaccines against SARS-CoV-2. Albanian Journal of Trauma and Emergency Surgery, 5(1), 791796. doi:10.32391/ajtes.v5i1.178
Thomas, S. J., Moreira, E. D., Jr, Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., C4591001 Clinical Trial Group. (2021). Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine through 6 months. The New England Journal of Medicine, 385(19), 17611773. doi:10.1056/NEJMoa2110345
Heath, P. T., Galiza, E. P., Baxter, D. N., Boffito, M., Browne, D., Burns, F., 2019nCoV-302 Study Group. (2021). Safety and efficacy of NVX-CoV2373 covid-19 vaccine. The New England Journal of Medicine, 385(13), 11721183. doi:10.1056/NEJMoa2107659
Houser, K. V., Chen, G. L., Carter, C., Crank, M. C., Nguyen, T. A., Burgos Florez, M. C., VRC 316 Study Team. (2022). Safety and immunogenicity of a ferritin nanoparticle H2 influenza vaccine in healthy adults: a phase 1 trial. Nature Medicine, 28(2), 383391. doi:10.1038/s41591-021-01660-8
Shinde, V., Bhikha, S., Hoosain, Z., Archary, M., Bhorat, Q., Fairlie, L., 2019nCoV-501 Study Group. (2021). Efficacy of NVX-CoV2373 Covid-19 vaccine against the B.1.351 variant. The New England Journal of Medicine, 384(20), 18991909. doi:10.1056/NEJMoa2103055
Dunkle, L. M., Kotloff, K. L., Gay, C. L., ez, G., Adelglass, J. M., Barrat Hernndez, A. Q., 2019nCoV-301 Study Group. (2022). Efficacy and safety of NVX-CoV2373 in adults in the United States and Mexico. The New England Journal of Medicine, 386(6), 531543. doi:10.1056/NEJMoa2116185
Wei, L., Zhao, T., Zhang, J., Mao, Q., Gong, G., Sun, Y., Wu, Y. (2022). Efficacy and safety of a nanoparticle therapeutic vaccine in patients with chronic hepatitis B: A randomized clinical trial. Hepatology (Baltimore, Md.), 75(1), 182195. doi:10.1002/hep.32109
Sahin, U., Muik, A., Vogler, I., Derhovanessian, E., Kranz, L. M., Vormehr, M., Treci, . (2021). BNT162b2 vaccine induces neutralizing antibodies and poly-specific T cells in humans. Nature, 595(7868), 572577. doi:10.1038/s41586-021-03653-6
Datoo, M. S., Natama, M. H., Som, A., Traor, O., Rouamba, T., Bellamy, D., Tinto, H. (2021). Efficacy of a low-dose candidate malaria vaccine, R21 in adjuvant Matrix-M, with seasonal administration to children in Burkina Faso: a randomised controlled trial. Lancet, 397(10287), 18091818. doi:10.1016/S0140-6736(21)00943-0
Toback, S., Galiza, E., Cosgrove, C., Galloway, J., Goodman, A. L., Swift, P. A., 2019nCoV-302 Study Group. (2022). Safety, immunogenicity, and efficacy of a COVID-19 vaccine (NVX-CoV2373) co-administered with seasonal influenza vaccines: an exploratory substudy of a randomised, observer-blinded, placebo-controlled, phase 3 trial. The Lancet. Respiratory Medicine, 10(2), 167179. doi:10.1016/S2213-2600(21)00409-4
Maruggi, G., Mallett, C. P., Westerbeck, J. W., Chen, T., Lofano, G., Friedrich, K., Yu, D. (2022). A self-amplifying mRNA SARS-CoV-2 vaccine candidate induces safe and robust protective immunity in preclinical models. Molecular Therapy: The Journal of the American Society of Gene Therapy, 30(5), 18971912. doi:10.1016/j.ymthe.2022.01.001
Madhi, S. A., Moodley, D., Hanley, S., Archary, M., Hoosain, Z., Lalloo, U., 2019nCoV-501 Study Group. (2022). Immunogenicity and safety of a SARS-CoV-2 recombinant spike protein nanoparticle vaccine in people living with and without HIV-1 infection: a randomised, controlled, phase 2A/2B trial. The Lancet. HIV, 9(5), e309e322. doi:10.1016/S2352-3018(22)00041-8
Stuart, A. S. V., Shaw, R. H., Liu, X., Greenland, M., Aley, P. K., Andrews, N. J., Com-COV2 Study Group. (2022). Immunogenicity, safety, and reactogenicity of heterologous COVID-19 primary vaccination incorporating mRNA, viral-vector, and protein-adjuvant vaccines in the UK (Com-COV2): a single-blind, randomised, phase 2, non-inferiority trial. Lancet, 399(10319), 3649. doi:10.1016/S0140-6736(21)02718-5
Aldrich, C., Leroux-Roels, I., Huang, K. B., Bica, M. A., Loeliger, E., Schoenborn-Kellenberger, O., Oostvogels, L. (2021). Proof-of-concept of a low-dose unmodified mRNA-based rabies vaccine formulated with lipid nanoparticles in human volunteers: A phase 1 trial. Vaccine, 39(8), 13101318. doi:10.1016/j.vaccine.2020.12.070
Shinde, V., Cho, I., Plested, J. S., Agrawal, S., Fiske, J., Cai, R., Glenn, G. M. (2022). Comparison of the safety and immunogenicity of a novel Matrix-M-adjuvanted nanoparticle influenza vaccine with a quadrivalent seasonal influenza vaccine in older adults: a phase 3 randomised controlled trial. The Lancet Infectious Diseases, 22(1), 7384. doi:10.1016/S1473-3099(21)00192-4
Formica, N., Mallory, R., Albert, G., Robinson, M., Plested, J. S., Cho, I., 2019nCoV-101 Study Group. (2021). Different dose regimens of a SARS-CoV-2 recombinant spike protein vaccine (NVX-CoV2373) in younger and older adults: A phase 2 randomized placebo-controlled trial. PLoS Medicine, 18(10), e1003769. doi:10.1371/journal.pmed.1003769
H S, R., Khobragade, A., Satapathy, D., Gupta, M., Kumar, S., Bhomia, V., Agrawal, A. D. (2021). Safety and Immunogenicity of a novel three-dose recombinant nanoparticle rabies G protein vaccine administered as simulated post exposure immunization: A randomized, comparator controlled, multicenter, phase III clinical study. Human Vaccines & Immunotherapeutics, 17(11), 42394245. doi:10.1080/21645515.2021.1957413
August, A., Attarwala, H. Z., Himansu, S., Kalidindi, S., Lu, S., Pajon, R., Zaks, T. (2021). A phase 1 trial of lipid-encapsulated mRNA encoding a monoclonal antibody with neutralizing activity against Chikungunya virus. Nature Medicine, 27(12), 22242233. doi:10.1038/s41591-021-01573-6
Shinde, V., Cai, R., Plested, J., Cho, I., Fiske, J., Pham, X., Glenn, G. M. (2021). Induction of cross-reactive hemagglutination inhibiting antibody and polyfunctional CD4+ T-cell responses by a recombinant Matrix-M-adjuvanted hemagglutinin nanoparticle influenza vaccine. Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America, 73(11), e4278e4287. doi:10.1093/cid/ciaa1673
Kremsner, P. G., Mann, P., Kroidl, A., Leroux-Roels, I., Schindler, C., Gabor, J. J., CV-NCOV-001 Study Group. (2021). Safety and immunogenicity of an mRNA-lipid nanoparticle vaccine candidate against SARS-CoV-2 : A phase 1 randomized clinical trial: A phase 1 randomized clinical trial. Wiener Klinische Wochenschrift, 133(1718), 931941. doi:10.1007/s00508-021-01922-y
Mallory, R. M., Formica, N., Pfeiffer, S., Wilkinson, B., Marcheschi, A., Albert, G., Novavax 2019nCoV101 Study Group. (2022). Safety and immunogenicity following a homologous booster dose of a SARS-CoV-2 recombinant spike protein vaccine (NVX-CoV2373): a secondary analysis of a randomised, placebo-controlled, phase 2 trial. The Lancet Infectious Diseases, 22(11), 15651576. doi:10.1016/S1473-3099(22)00420-0
Heath, P. T., Galiza, E. P., Baxter, D. N., Boffito, M., Browne, D., Burns, F., Toback, S. (2023). Safety and efficacy of the NVX-CoV2373 Coronavirus disease 2019 vaccine at completion of the placebo-controlled phase of a randomized controlled trial. Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America, 76(3), 398407. doi:10.1093/cid/ciac803
Lovell, J. F., Baik, Y. O., Choi, S. K., Lee, C., Lee, J.-Y., Miura, K., Choi, J.-H. (2022). Interim analysis from a phase 2 randomized trial of EuCorVac-19: a recombinant protein SARS-CoV-2 RBD nanoliposome vaccine. BMC Medicine, 20(1), 462. doi:10.1186/s12916-022-02661-1
Gatechompol, S., Kittanamongkolchai, W., Ketloy, C., Prompetchara, E., Thitithanyanont, A., Jongkaewwattana, A., ChulaVAC-001 study team. (2022). Safety and immunogenicity of a prefusion non-stabilized spike protein mRNA COVID-19 vaccine: a phase I trial. Nature Microbiology, 7(12), 19871995. doi:10.1038/s41564-022-01271-0
Masuda, T., Murakami, K., Sugiura, K., Sakui, S., Schuring, R. P., & Mori, M. (2022). Safety and immunogenicity of NVX-CoV2373 (TAK-019) vaccine in healthy Japanese adults: Interim report of a phase I/II randomized controlled trial. Vaccine, 40(24), 33803388. doi:10.1016/j.vaccine.2022.04.035
Ishikawa, T., Kageyama, S., Miyahara, Y., Okayama, T., Kokura, S., Wang, L., Shiku, H. (2021). Safety and antibody immune response of CHP-NY-ESO-1 vaccine combined with poly-ICLC in advanced or recurrent esophageal cancer patients. Cancer Immunology, Immunotherapy: CII, 70(11), 30813091. doi:10.1007/s00262-021-02892-w
Li, J., Hui, A.-M., Zhang, X., Ge, L., Qiu, Y., Tang, R., Zhu, F. (2022). Immune persistence and safety after SARS-CoV-2 BNT162b1 mRNA vaccination in Chinese adults: A randomized, placebo-controlled, double-blind phase 1 trial. Advances in Therapy, 39(8), 37893798. doi:10.1007/s12325-022-02206-1
Wei, J., Cheng, X., Zhang, Y., Gao, C., Wang, Y., Peng, Q., Gu, J. (2021). Identification and application of a neutralizing epitope within alpha-hemolysin using human serum antibodies elicited by vaccination. Molecular Immunology, 135, 4552. doi:10.1016/j.molimm.2021.03.028
DOI: https://doi.org/10.14421/biomedich.2023.121.343-361
Refbacks
- There are currently no refbacks.
Copyright (c) 2023 Mohamed Hussein, Madiha Mumtaz, Iqra Nasir, Anisa Abdullahi
Biology, Medicine, & Natural Product Chemistry |